DDInter413 DDInter1376
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clopidogrel {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Clopidogrel {u} (Compound) treats {v} (Disease) coronary artery disease
Clopidogrel {u} (Compound) binds {v} (Gene) P2RY12
Clopidogrel {u} (Compound) upregulates {v} (Gene) TBXA2R
Clopidogrel {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Clopidogrel {u} (Compound) downregulates {v} (Gene) DECR1
Clopidogrel {u} (Compound) causes {v} (Side Effect) Deafness
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluvastatin
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Modafinil
Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Clopidogrel (Compound) treats coronary artery disease (Disease)
Clopidogrel (Compound) binds P2RY12 (Gene)
Clopidogrel (Compound) upregulates TBXA2R (Gene)
Clopidogrel (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Clopidogrel (Compound) downregulates DECR1 (Gene)
Clopidogrel (Compound) causes Deafness (Side Effect)
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fluvastatin
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Torasemide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Modafinil